Jackson Creek Investment Advisors LLC Invests $301,000 in Exelixis, Inc. (NASDAQ:EXEL)

Jackson Creek Investment Advisors LLC bought a new position in shares of Exelixis, Inc. (NASDAQ:EXEL) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 9,045 shares of the biotechnology company’s stock, valued at approximately $301,000.

Several other institutional investors also recently modified their holdings of the stock. Ashton Thomas Private Wealth LLC acquired a new position in shares of Exelixis during the 4th quarter worth about $240,000. E Fund Management Co. Ltd. grew its position in shares of Exelixis by 5.9% during the 4th quarter. E Fund Management Co. Ltd. now owns 15,055 shares of the biotechnology company’s stock worth $501,000 after buying an additional 844 shares during the period. Candriam S.C.A. grew its position in shares of Exelixis by 12.1% during the 4th quarter. Candriam S.C.A. now owns 614,671 shares of the biotechnology company’s stock worth $20,469,000 after buying an additional 66,552 shares during the period. Inceptionr LLC acquired a new position in shares of Exelixis during the 4th quarter worth about $814,000. Finally, Raymond James Financial Inc. acquired a new position in shares of Exelixis in the 4th quarter valued at approximately $17,046,000. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, EVP Patrick J. Haley sold 52,636 shares of the company’s stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $36.98, for a total value of $1,946,479.28. Following the transaction, the executive vice president now owns 303,310 shares of the company’s stock, valued at approximately $11,216,403.80. This represents a 14.79 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Mary C. Beckerle sold 12,210 shares of the company’s stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $34.88, for a total value of $425,884.80. Following the completion of the transaction, the director now directly owns 30,406 shares in the company, valued at $1,060,561.28. The trade was a 28.65 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 140,343 shares of company stock valued at $5,177,234 over the last 90 days. 2.85% of the stock is currently owned by insiders.

Exelixis Stock Up 1.0 %

Shares of NASDAQ EXEL opened at $38.58 on Friday. The business’s 50 day moving average price is $34.99 and its two-hundred day moving average price is $32.08. The company has a market cap of $10.80 billion, a PE ratio of 21.80, a price-to-earnings-growth ratio of 1.13 and a beta of 0.57. Exelixis, Inc. has a twelve month low of $20.14 and a twelve month high of $39.30.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. As a group, research analysts anticipate that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on EXEL shares. Truist Financial boosted their price objective on Exelixis from $42.00 to $43.00 and gave the company a “buy” rating in a research report on Monday, January 27th. JMP Securities reiterated a “market outperform” rating and issued a $41.00 price objective on shares of Exelixis in a research report on Thursday, January 23rd. Wells Fargo & Company lowered Exelixis from an “overweight” rating to an “equal weight” rating and set a $36.00 price objective for the company. in a research report on Monday, February 24th. StockNews.com upgraded Exelixis from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, February 19th. Finally, Guggenheim reiterated a “buy” rating and issued a $42.00 price objective on shares of Exelixis in a research report on Wednesday, February 12th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $37.24.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.